Lutetium-177 [(177)Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

Kostos L, Buteau JP, Xie J, Cardin A, Akhurst T, Alipour R, Au L, Chan J, Chin KY, Emmerson B, Furic L, Garcia Q, Hamilton AJ, Haskali MB, Jackson PA, Kashyap RK, Kong G, MacFarlane L, Murphy DG, Parker BS, Ravi Kumar AS, Saghebi J, Wang Y, Tran B, Azad AA, Hofman MS

Open source

DOI: 10.1016/s1470-2045(25)00559-5
Published: 2025 Nov
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00559-5,
  title = {Lutetium-177 [(177)Lu]Lu-PSMA-I\&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.},
  author = {Kostos L and Buteau JP and Xie J and Cardin A and Akhurst T and Alipour R and Au L and Chan J and Chin KY and Emmerson B and Furic L and Garcia Q and Hamilton AJ and Haskali MB and Jackson PA and Kashyap RK and Kong G and MacFarlane L and Murphy DG and Parker BS and Ravi Kumar AS and Saghebi J and Wang Y and Tran B and Azad AA and Hofman MS},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00559-5},
  url = {https://doi.org/10.1016/s1470-2045(25)00559-5}
}

RIS

TY  - JOUR
TI  - Lutetium-177 [(177)Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
AU  - Kostos L
AU  - Buteau JP
AU  - Xie J
AU  - Cardin A
AU  - Akhurst T
AU  - Alipour R
AU  - Au L
AU  - Chan J
AU  - Chin KY
AU  - Emmerson B
AU  - Furic L
AU  - Garcia Q
AU  - Hamilton AJ
AU  - Haskali MB
AU  - Jackson PA
AU  - Kashyap RK
AU  - Kong G
AU  - MacFarlane L
AU  - Murphy DG
AU  - Parker BS
AU  - Ravi Kumar AS
AU  - Saghebi J
AU  - Wang Y
AU  - Tran B
AU  - Azad AA
AU  - Hofman MS
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00559-5
UR  - https://doi.org/10.1016/s1470-2045(25)00559-5
ER  -

APA

L, K., JP, B., J, X., A, C., T, A., R, A., L, A., J, C., KY, C., B, E., L, F., Q, G., AJ, H., MB, H., PA, J., RK, K., G, K., L, M., DG, M., BS, P., AS, R. K., J, S., Y, W., B, T., AA, A., & MS, H. (2025). Lutetium-177 [(177)Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00559-5

Source records

pubmed · retrieved 2026-09-27T09:29:34.230Z